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B-type natriuretic peptide (BNP) is a cardiac
neurohormone that has recently been described as
a diagnostic and prognostic marker for patients
with congestive heart failure [1–3]. In several stud-
ies, BNP has turned out to be superior to the clin-
ically used atrial natriuretic peptide (ANP) in
terms of sensitivity as well as specificity [4]. The
mRNA of BNP contains four repetitive AUUUA
sequences, which lead to its destabilisation and en-
able the synthesis of BNP in bursts [5, 6]. BNP
therefore reflects haemodynamic changes more
accurately than ANP. 
BNP is synthesised and stored mainly in car-
diac ventricles. Increased synthesis and release of
BNP occur in response to ventricular volume ex-
pansion and pressure overload [7–9]. Adequate
therapy of congestive heart failure decreases wall
stress and, thus, leads to a decrease of BNP plasma
levels. In end-stage heart failure, medical therapy
may be ineffective in reducing haemodynamic
overload and diminishing consecutively neurohu-
moral stimulation. Thus, changes in plasma BNP
reflect treatment-responsiveness of heart failure.
Patients with persistently high plasma BNP de-
spite adequate heart failure treatment are likely to
have a worse prognosis than patients with a signif-
icant decrease in plasma BNP under therapy [3]. 
Current standard criteria for the diagnosis of
heart failure include the presence of symptoms of
heart failure, objective evidence of cardiac dys-
Background: Prognostic classification of con-
gestive heart failure (CHF) is difficult and only
possible with the help of additional diagnostic
tools. B-type natriuretic peptide (BNP) has been
used as a diagnostic and prognostic marker for pa-
tients (pts) with CHF. In this study, the clinical
value of BNP for stratification and treatment of pts
with CHF was evaluated.
Patients and methods: 33 out-pts with CHF (age
57 ± 12 years) were included. Left-ventricular (LV)
ejection fraction (EF) was 27 ± 8% (mean ± SD)
and NYHA-class 2.4 ± 0.7. Following  parameters
were measured: BNP and sodium from blood sam-
ples, exercise performance from 6-minute walking
test (6MWT, meters) (n = 18), LV end-diastolic di-
ameter (LVEDD) and LV mass (LVM) from 2D-
echocardiography (n = 33), as well as LV end-dias-
tolic pressure (LVEDP, n = 23) and systemic vas-
cular resistance (SVR, n = 20) from heart-catheter-
isation. Ten pts were hospitalised in the preceding
6 months because of worsening CHF or for opti-
misation of medical therapy. BNP was measured at
the beginning and end of the hospital-stay. Follow-
up was for 1 year.
Results: Pts with a high NYHA-class had a
higher BNP (pg/ml) than those with a low NYHA-
class: NYHA I 51 ± 20, II 281 ± 223, III 562 ± 346
and IV 1061 ± 126 pg/ml (p = 0.002). BNP corre-
lated with LVEDP (r = 0.50, p <0.02), SVR (r =
0.49, p <0.03) and inversely with 6MWT (r =
–0.60, p <0.009), LVEF (r = –0.49, p <0.004) and
sodium (r = –0.36, p = 0.04). In the hospitalised pts,
mean BNP (pg/ml) was 881 ± 695 at admission,
and 532 ± 435 at discharge (n.s.). Decrease in BNP
during hospitalisation paralleled weight-loss and
was significantly greater in patients with >1000
pg/ml BNP at admission (n = 5) as compared to the
5 patients with BNP <1000 (p <0.03). Patients with
an adverse event during 1-year follow-up had sig-
nificantly higher BNP both at steady-state (603 ±
359 pg/ml) and at time of decompensation than pa-
tients with a favourable outcome (227 ± 218 pg/ml,
p <0.001). 
Conclusions: BNP correlates well with the clin-
ical severity of CHF (NYHA-class) and is directly
related to filling pressure (LVEDP), LV function
(LVEF) and exercise performance (6 MWT). Fur-
thermore, BNP has prognostic impact with regard
to adverse clinical events.
Key words: congestive heart failure; neurohumoral
stimulation; natriuretic peptides
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function and appropriate response to heart failure
treatment [10]. Whereas cardiac function is mainly
assessed by echocardiography, estimation of treat-
ment-responsiveness is usually based on clinical
judgement. BNP may provide an additional tool
for estimation of treatment-responsiveness as well
as for triage of patients with heart failure-like
symptoms who need further investigation by
echocardiography. 
In the present study, a small cohort with stable
or decompensated heart failure patients were eval-
uated to assess clinical benefit of bedside BNP
measurements for risk stratification of patients
with congestive heart failure in every-day clinical
practice.
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Patients and methods
Study population
Thirty-three consecutive outpatients presenting in
the heart-failure out-patient department of our university
hospital with chronic heart failure NYHA I–IV and a left-
ventricular ejection fraction ≤45% at echocardiography
were included in the study. Patients with isolated diastolic
dysfunction, right-heart failure, primary pulmonary hy-
pertension or congenital heart disease were excluded from
the present analysis. Treatment consisted of standard heart
failure therapy including RAAS antagonists, beta-adren-
ergic blockers and diuretics. Medication was stable for at
least two weeks before blood sampling (most for >3
months). Furthermore, patients had to be clinically stable
and on constant doses of diuretics. The following labora-
tory parameters were determined at baseline: BNP, plasma
sodium and potassium, exercise performance from 
6-minute walking test (6MWT, meters, n = 18), left ven-
tricular end-diastolic diameter (LVEDD) and left ventric-
ular mass (LVM) from 2D-echocardiography (n = 33), as
well as left ventricular end-diastolic pressure (LVEDP, 
n = 23) and systemic vascular resistance (SVR, n = 20) from
heart-catheterisation. 
Ten of the 33 patients presenting with dyspnoea
NYHA class III or IV were hospitalised within the pre-
ceding six months before steady state blood sampling be-
cause of worsening heart failure or need for optimisation
of medical therapy. Diuretic therapy had to be intensified
in all patients, either by an increase in the orally adminis-
tered drug, or by addition of an IV-diuretic. Furthermore,
transient vasodilator treatment was established in three
patients, and three other patients had to be treated with
IV-catecholamines. Duration of the hospital stay was be-
tween five and 14 days. BNP was measured at the begin-
ning and the end of the hospital stay. Clinical follow-up
was 1 year for all 33 patients. 
Ethics
Informed consent was obtained from all patients for
blood sampling and inclusion into the study. Echocardio-
gram, heart catheterisation, and six minute walking test
were based on clinical indications. 
Measurement of BNP plasma levels
Four millilitre of blood was drawn from an antecu-
bital vein into an ethylen-diamine-tetra-actetate contain-
ing tube. During blood collection, the patient remained in
a sitting position. No exercise was allowed for one hour
before blood sampling. Plasma B-type natriuretic peptide
was measured using the Triage B-Type Natriuretic Pep-
tide test (Biosite Diagnostics Inc., San Diego, California),
as described elsewhere [1]. The Triage BNP test is a fluo-
rescence immunoassay for quantification of the biologi-
cally active BNP-32 in whole blood or plasma samples.
BNP-32 levels as determined by the Triage kit have
demonstrated excellent correlations with the more re-
cently described amino-terminal pro BNP plasma levels
with a longer half-life time [11]. 
Statistical analysis
In tables and figures, mean values 8 1 standard devi-
ation are given. Correlations were determined with the
Spearman-rank test, statistical differences between groups
with the Kruskal-Wallis or the Mann-Whitney U-test. A
p value <0.05 was considered statistically significant. For
assessment of the accuracy of the steady-state BNP value
to predict an adverse event during 1-year follow-up, a re-
ceiver operating characteristic curve (ROC) was com-
puted. A multivariate analysis was not performed due to
the small sample size. However, a univariate analysis was
carried out. For statistical analyses, the SPSS package and
“analyse-it” statistical programs were used. 
Results
Patient characteristics including aetiology of
heart failure and medication at the time of blood
sampling are given in table 1. With increasing
NYHA-class, BNP levels (mean ± SD) increased:
from 51 ± 20 pg/ml in patients with NYHA-class
I to 281 ± 223 pg/ml in patients with NYHA-class
II, 562 ± 346 pg/ml in patients with NYHA-class
III, and 1061 ± 126 pg/ml in patients with NYHA-
class IV (p = 0.002, fig. 1). 
Correlations
Significant positive correlations were found
between BNP and left ventricular end-diastolic
pressure (r = 0.50, p <0.02) and systemic vascular
resistance (r = 0.49, p <0.03, Fig. 2). Furthermore,
there were significant inverse correlations between
BNP and left ventricular ejection fraction (r =
–0.49, p <0.004) and physical performance (walking
distance, m) assessed by the six minute walking test
(r = –0.60, p <0.009, Fig. 3). According to the
natriuretic effect of BNP, plasma BNP levels were
significantly inverse correlated to sodium (r =
–0.36, p = 0.04). No correlation existed between
BNP and age, left ventricular end-diastolic diam-
eter, left ventricular mass, and body mass index
(mean ± SD 25.8 ± 4.3 kg/m2). 
Subgroups
Table 2 shows patient characteristics of the
hospitalised patients (n = 10) including aetiology
of heart failure and medication at hospital admis-
sion. Mean BNP (pg/ml) was 881 ± 695 at admis-
sion, and 532 ± 435 at discharge (n.s.). Five patients
(group 1) had a BNP >1000 pg/ml (1465 ± 472) at
admission, and five (group 2) <1000 (299 ± 109).
Left ventricular ejection fraction was significantly
lower in group 1 than 2 (19 ± 3 vs. 31 ± 9%, p =
0.012). BNP decreased in both groups with ther-
apy, but significantly more in group 1 than 2: –582
± 385 vs. –117 ± 78, p = 0.028. The decrease in BNP
paralleled weight loss in the two groups, which also
was significantly more pronounced in group 1 than
2: –5.1 ± 3.3 kg vs. –0.3 ± 1.2 kg (p = 0.009, fig. 4). 
Follow-up
During a twelve-month follow-up period two
of the ten hospitalised patients died in group 1, but
none in group 2. One other group 1 patient was
successfully transplanted. In group 2, three pa-
tients had to be re-hospitalised, one each for wors-
ening heart failure, atrial flutter, and evaluation of
a cardiac tumour, respectively. Two patients in each
group remained clinically stable with no need for
re-hospitalisation throughout follow-up. 
Overall, 16/33 patients exhibited a major ad-
verse clinical event (MACE) such as death (n = 5),
heart transplantation (n = 4), or re-hospitalisation
for worsening heart failure (n = 4), arrhythmia 
(n = 1), or surgery (n = 2) in case of coronary, val-
vular or other heart disease (cardiac tumour), re-
spectively. Patients with MACE had significantly
higher steady-state BNP levels than patients with-
out MACE (603 8 359 vs. 227 8 218 pg/ml, p =
0.0003). Furthermore, BNP levels of patients who
underwent heart transplantation or died were sig-
nificantly higher (782 8 376 pg/ml) than those of
patients re-hospitalised for other cardiac reasons
(373 8 152, p = 0.023). BNP values in patients with
minor clinical events were also significantly higher
than in patients without re-hospitalisation (373 8
152 vs. 227 8 218 pg/ml, p = 0.033). 
The receiver operator curve, shown in figure
5, depicts the sensitivity and specificity of BNP
steady-state values in discriminating patients who
will have an adverse event (death, heart transplan-
tation or re-hospitalisation) in 1 year of follow-up.
The area under the receiver operator curve was
0.868, indicating a high discriminatory power. 
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range
Gender (m:f) 26:7
Age (years, mean ± SD, [range]) 57 ± 12 (31–80)
NYHA-class 2.4 ± 0.7
Left ventricular ejection fraction (%) 27 ± 8 (15–45*)
Etiology of heart failure 
dilated cardiomyopathy* 17
coronary artery disease 11
valvular heart disease 3
anthracycline-induced cardiomyopathy 1
myocarditis 1
Medication at index visit n
Diuretics 30 91%
Angiotensin-converting-enzyme inhibitors 30 91%
Angiotensin receptor blockers 3 9%
Beta-adrenergic blockers 22 67%
Spironolactone 23 70%
Digitalis 12 36%
Nitrates 6 18%
Amiodarone 11 33%
Salicylic Acid 5 15%
Coumadine 27 82%
* including one patient with left-ventricular ejection fraction 
of 45% and diagnosis of an intracardiac tumour
Table 1
Patient characteris-
tics of outpatients
(n = 33).
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Figure 1
Relationship 
between BNP levels
(mean ± SD) and
NYHA-class.
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Figure 2
Correlation between
BNP and LVEDP (left)
as well as BNP and
SVR (right).
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A significant correlation between BNP and
clinical severity of CHF in terms of NYHA-class
was found in 33 clinically stable outpatients. Fur-
thermore, BNP was significantly correlated with
filling pressure (LVEDP), left ventricular ejection
fraction (LVEF) and exercise performance (6
MWT), but correlation between BNP and walk-
ing distance in the 6 MWT was stronger than with
ejection fraction. Hospitalised patients with a high
BNP at admission had a worse clinical outcome
during 1 year follow-up than those with a low BNP.
The same holds true for steady-state BNP, which
was significantly higher in the 16 patients suffer-
ing a major cardiac event within 1 year of follow-
up as compared to 17 patients with an uncompli-
cated clinical course.
BNP and severity of CHF
In the 33 clinically stable outpatients without
signs of water retention, a significant correlation
was found between BNP and NYHA-class as al-
ready described in other studies [9, 12]. The stim-
ulus for increased BNP synthesis is the stretch of
cardiomyocytes by an increased wall stress [13].
Thus, BNP levels can be expected to increase with
diastolic filling pressures and peripheral vascular
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Figure 3
Correlation between
BNP and LVEF (left)
as well as physical
exercise performance
as estimated by the
walking distance
(right).
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Figure 5
Receiver Operator
Characteristic (ROC)
curve for BNP versus
adverse cardiac
events (death, rehos-
pitalization, cardiac
transplantation). For
BNP >300 pg/ml the
negative predictive
value is 87.5% and
the positive predic-
tive value 82.3%.
Discussion
range
Gender (m:f) 9:1
Age (years, mean ± SD) 62 ± 14 (36–66)
Left ventricular ejection fraction (%) 25 ± 9 (20–45*)
Etiology of heart failure 
dilated cardiomyopathy* 7 
coronary artery disease 3
Medication at admission n
Diuretics 10 100%
Angiotensin-converting-enzyme inhibitors 7 70%
Angiotensin receptor blockers 2 20%
Beta-adrenergic blockers 4 40%
Spironolactone 9 90%
Digitalis 2 20%
Nitrates 2 20%
Amiodarone 5 50%
Salicylic Acid 2 20%
Coumadine 5 50%
* including one patient with left-ventricular ejection fraction 
of 45% and diagnosis of an intracardiac tumor
Table 2
Patient characteristics of hospitalised patients (n = 10).
resistance, which both are the case in the present
study. Since elevated filling pressures directly cor-
relate with worsening heart failure symptoms, the
correlation of BNP with NYHA-class can be an-
ticipated as well. 
NYHA-classification is still one of the major
means for describing clinical presentation and
severity of CHF, yet it is a subjective measure con-
founded by personal judgement. The wide overlap
of BNP levels observed in our study population es-
pecially between NYHA-class II and III patients is
characteristic for the varying degree in cardiac
haemodynamics and neurohumoral stimulation in
patients presenting with a similar functional status.
Thus, BNP allows a more precise and objective as-
sessment of the severity of CHF than NYHA-clas-
sification alone. This could be important in the
long-term follow-up of CHF patients especially in
the out-patient setting.
BNP in decompensated CHF
In hospitalised patients, BNP was >1000 pg/ml
at admission in half of them, and <1000 pg/ml in
the others. In both subgroups, BNP levels could
be lowered under intensified therapy, whereby the
decrease in BNP paralleled weight loss and clini-
cal improvement in terms of NYHA-class. Fatal
outcome in terms of death or heart transplantation
occurred in three patients with persistently high
BNP despite adequate therapy. Thus, BNP levels
at discharge and the course of BNP under treat-
ment reflect treatment-responsiveness of CHF pa-
tients and may be a predictor for clinical course and
outcome. Although the change in BNP levels
under treatment goes parallel with clinical im-
provement, recent studies indicated that adjust-
ment of medical therapy with dose increases results
in a further decrease of BNP despite stable clini-
cal findings (NYHA-class, signs of congestion), in-
dicating a higher degree of neurohumoral adapta-
tion and probably better long-term stabilisation
[14, 15].
BNP and risk-stratification of CHF
Several recent studies suggested BNP as im-
portant prognostic marker for CHF patients [2, 3,
16]. The worse outcome during 1 year follow-up
of our hospitalised patients with high BNP levels
at admission and insufficient response to adequate
therapy indicates the possible usefulness of BNP
for risk stratification in decompensated CHF
patients. Consistently, Cheng and co-workers
demonstrated in a group of 72 patients with de-
compensated heart failure, that BNP at admission
as well as at discharge, and the change of BNP
under treatment are predictors for an adverse out-
come in terms of re-hospitalisation, death and
worsening heart failure within 30 days after dis-
charge [3]. Furthermore, 16 of our 33 clinically sta-
ble out-patients experienced an adverse cardiac
event within 1 year after steady-state blood sam-
pling. Steady-state BNP values were significantly
higher in those 16 patients as compared to the 17
patients with a favourable clinical outcome,
whereby BNP was highest in patients who died or
underwent cardiac transplantation. These data are
in agreement with the findings of Tsutamoto et al.,
who described BNP as a significant independent
predictor of mortality in a cohort of 85 patients
with chronic CHF followed for 2 years [16]. 
In the clinically stable outpatients, a significant
negative correlation between BNP and LVEF was
found on the one hand, and physical performance
as assessed by the 6 MWT on the other. Interest-
ingly, BNP seemed to be more strongly correlated
to the walking distance (6 MWT) than to LVEF.
Since resting LVEF only modestly reflects LVEF
under exercise, and does not provide any informa-
tion about diastolic function and wall stress, it is
obvious that LVEF can be only a poor indicator for
exercise tolerance and functional capacity in pa-
tients with CHF [17, 18]. Assessment of functional
aerobic capacity is associated with great prognos-
tic impact in CHF patients, where peak oxygen
consumption (peak VO2) represents the gold stan-
dard. However, the walking distance assessed by
the 6 MWT has been shown to be closely related
to peak VO2 [19, 20] and to represent an inde-
pendent predictor of morbidity and mortality [21]. 
Clinical implications
Our study adds to the increasing evidence that
BNP significantly contributes not only to the as-
sessment of clinical severity but also of long-term
prognosis in CHF patients and, thus, might be
used as a “bed-side test” in every-day clinical prac-
tice. The receiver operator curve indicated a high
discriminating power (area under the curve 0.868)
for identifying patients at high risk for adverse car-
diac events during 1 year follow-up. However, the
number of patients included in this study is rela-
tively small. Certainly, more and larger studies are
needed to confirm these data and to provide
enough evidence to allow routine application of
BNP for the assessment of CHF patients in the 
in- and out-patient CHF clinic. 
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